LT3:FRA
AxoGen, Inc Common Stock
€30.69
arrow_downward
-1.13%(-0.35) 1D
Oct 19, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LT3...
Open
€30.24
High
€30.69
Low
€30.24
Mkt. cap
2.06B
Avg. vol.
5.00
Volume
0.00
52-wk high
€44.33
52-wk low
€13.70
No. of employees
622
Open
€30.24
High
€30.69
Low
€30.24
Mkt. cap
2.06B
Avg. vol.
5.00
Volume
0.00
52-wk high
€44.33
52-wk low
€13.70
No. of employees
622
News stories
From web sources and news partners
Action Forex
·
51 minutes ago
The S&P 500 Is on a Dangerous Path
Crypto Briefing
·
5 hours ago
AI stocks now make up 49% of the S&P 500, the second-highest concentration on record
Investing.com
·
5 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
TradingView
·
6 hours ago
There is no fundamental reason for stocks’ reversal, says SA analyst
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com